-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Gan Lai Pharmaceutical announced on February 21 that its liver-targeted prodrug ASC41 has achieved good results in clinical trials in overweight and obese subjects.
In this randomized, double-blind, placebo-controlled clinical study, the study population consisted of 20 overweight and obese subjects with low-density lipoprotein cholesterol (LDL-C) greater than 110 mg/dL.
During the 28-day treatment, ASC41 was relatively safe.
Note: The original text has been deleted